Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.

NCT07684898 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Hemophilia A

Interventions

DRUG: FRSW107

Sponsor

Hangzhou Gensciences Biopharmaceutical Co., Ltd.